Activated protein C resistance in patients following venous thromboembolism receiving rivaroxaban versus vitamin K antagonists: assessment using Russell viper venom time-based assay.
作者： Tadeusz Goralczyk , Katarzyna B. Wojtowicz , Anetta Undas
DOI: 10.1097/MBC.0000000000000597
关键词:
摘要: Activated protein C resistance (APC-R) is assessed as part of thrombophilia screening, preferably in patients not taking oral anticoagulants. Rivaroxaban known to alter some APC-R assays. To our knowledge, there have been no reports on the effect rivaroxaban Russell viper venom time (RV
sci-hub.se 参考文章(25)
Gianluca Gessoni, Francesca Gessoni, Sara Valverde, Roberto Valle, The effect of dabigatran and rivarovaban on a prothrombinase-based assay for activated protein C resistance: a preliminary study in subjects heterozygous for factor V Leiden. Blood Transfusion. ,vol. 13, pp. 666- 668 ,(2015) , 10.2450/2015.0224-14
Agon Mekaj, Ymer Mekaj, Shkelzen Duci, Ermira Miftari, New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Therapeutics and Clinical Risk Management. ,vol. 11, pp. 967- 977 ,(2015) , 10.2147/TCRM.S84210
Stephan Kadauke, Bernard Khor, Elizabeth M. Van Cott, Activated protein C resistance testing for factor V Leiden. American Journal of Hematology. ,vol. 89, pp. 1147- 1150 ,(2014) , 10.1002/AJH.23867
D.M. Adcock, R. Gosselin, Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review. Thrombosis Research. ,vol. 136, pp. 7- 12 ,(2015) , 10.1016/J.THROMRES.2015.05.001
Els Bailleul, Bernard Chatelain, Anne Demulder, Katrien Devreese, Jonathan Douxfils, Kristin Jochmans, François Mullier, Walter Wijns, Mohamed Rida Soumali, Wim Coucke, Kris Vernelen, Philippe Van de Walle, Marjan Van Blerk, Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thrombosis and Haemostasis. ,vol. 113, pp. 154- 164 ,(2014) , 10.1160/TH14-02-0161
A. HILLARP, F. BAGHAEI, I. FAGERBERG BLIXTER, K. M. GUSTAFSSON, L. STIGENDAL, M. STEN-LINDER, K. STRANDBERG, T. L. LINDAHL, Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. Journal of Thrombosis and Haemostasis. ,vol. 9, pp. 133- 139 ,(2011) , 10.1111/J.1538-7836.2010.04098.X
Heiko Rühl, Lars Schröder, Jens Müller, Rolf Fimmers, Shorena Sukhitashvili, Julia Welz, Walther C. Kuhn, Johannes Oldenburg, Christian Rudlowski, Bernd Pötzsch, Tamoxifen induces resistance to activated protein C. Thrombosis Research. ,vol. 133, pp. 886- 891 ,(2014) , 10.1016/J.THROMRES.2014.02.004
Adam Cuker, Deborah M. Siegal, Mark A. Crowther, David A. Garcia, Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. Journal of the American College of Cardiology. ,vol. 64, pp. 1128- 1139 ,(2014) , 10.1016/J.JACC.2014.05.065
Jody Lynn Kujovich, Factor V Leiden thrombophilia Genetics in Medicine. ,vol. 13, pp. 1- 16 ,(2011) , 10.1097/GIM.0B013E3181FAA0F2
Adrianna Z. Herskovits, Elizabeth A. Morgan, Susan J. Lemire, Neal I. Lindeman, David M. Dorfman, An Improved Algorithm for Activated Protein C Resistance and Factor V Leiden Screening American Journal of Clinical Pathology. ,vol. 140, pp. 379- 386 ,(2013) , 10.1309/AJCPO6VUP3MZEYWU